Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: Jim Cash who wrote (281)	2/20/1999 12:26:00 PM
From: Thomas Kirwin	Read Replies (1) \| Respond to of 422

Corp Com & IBD Musings Jim, I believe that Immucor made a wise selection with respects to Corporate Communications. It is my understanding that the price tag placed on their services is calculated at a flat rate. Some other PR/IR firms charge based on outstanding shares. (Example - $0.01 or greater per share) Corporate Communications wont break the bank or highly impact Immucor's earnings. I saw SERO highlighted in an Investor's Business Daily segment some time ago. Sure hope to see Immucor profiled in a similar fashion sometime soon. I like the company Corp Com keeps! Regards, Tom

To: Jim Cash who wrote (281)	2/27/1999 10:24:00 AM
From: Thomas Kirwin	Read Replies (1) \| Respond to of 422

3rd Q Earnings Guesstimate My best guess is that Immucor will report their 3rd quarter earnings ending February 28, 1999 on or before April 6, 1999 during market hours in the AM. EPS Guesstimate is $0.15 - $0.16. Last years actual 3rd Q EPS was $0.06. EPS increase/growth rate equal to or greater than 100%. Projected revenue increase is attributable to the Gamma Acquisition, sales of instruments not offered last year, increasing reagent sales and reduction of outstanding shares via the stock repurchase program. Update to follow in April '99. Go Immucor! Tom